{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Han G"],"funding":["National Natural Science Foundation of China"],"pagination":["873929"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9011333"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14"],"pubmed_abstract":["Energy metabolism disturbance and the consequent reactive oxygen species (ROS) overproduction play a key and pathogenic role in the onset and progression of Alzheimer's disease (AD). Dihuang-Yinzi (DHYZ) is a traditional Chinese herbal prescription clinically applied to treat AD and other neurodegenerative diseases for a long time. However, the systematical metabolic mechanism of DHYZ against AD remains largely unclear. Here we aimed to explore the mechanism of DHYZ in the treatment of AD comprehensively in an <i>in vivo</i> metabolic context by performing metabolomics analysis coupled with network pharmacology study and experimental validation. The network pharmacology was applied to dig out the potential target of DHYZ against AD. The metabolomics analysis based on UPLC-HRMS was carried "],"journal":["Frontiers in aging neuroscience"],"pubmed_title":["Dihuang-Yinzi Alleviates Cognition Deficits <i>via</i> Targeting Energy-Related Metabolism in an Alzheimer Mouse Model as Demonstrated by Integration of Metabolomics and Network Pharmacology."],"pmcid":["PMC9011333"],"funding_grant_id":["81673929","81973786"],"pubmed_authors":["Zhen W","Li D","Han G","Ma T","Dai Y","Yu H"],"additional_accession":[]},"is_claimable":false,"name":"Dihuang-Yinzi Alleviates Cognition Deficits <i>via</i> Targeting Energy-Related Metabolism in an Alzheimer Mouse Model as Demonstrated by Integration of Metabolomics and Network Pharmacology.","description":"Energy metabolism disturbance and the consequent reactive oxygen species (ROS) overproduction play a key and pathogenic role in the onset and progression of Alzheimer's disease (AD). Dihuang-Yinzi (DHYZ) is a traditional Chinese herbal prescription clinically applied to treat AD and other neurodegenerative diseases for a long time. However, the systematical metabolic mechanism of DHYZ against AD remains largely unclear. Here we aimed to explore the mechanism of DHYZ in the treatment of AD comprehensively in an <i>in vivo</i> metabolic context by performing metabolomics analysis coupled with network pharmacology study and experimental validation. The network pharmacology was applied to dig out the potential target of DHYZ against AD. The metabolomics analysis based on UPLC-HRMS was carried ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-04-08T17:39:59.021Z","creation":"2025-06-01T02:24:49.005Z"},"accession":"S-EPMC9011333","cross_references":{"pubmed":["35431901"],"doi":["10.3389/fnagi.2022.873929"]}}